ARS Pharmaceuticals (SPRY) Enterprise Value (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Enterprise Value of -$201.0 million for Q1 2026, up 17.97% sequentially from -$245.0 million in Q4 2025, and up 27.11% YoY from -$158.1 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Enterprise Value (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Enterprise Value for 7 years, with the latest figure at -$201.0 million in Q1 2026.
- Quarterly Enterprise Value rose 27.11% year-over-year to -$201.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$201.0 million (up 27.11% YoY) and the FY2025 annual result came in at -$245.0 million, up 21.98% from the prior year.
- Enterprise Value advanced to -$201.0 million in Q1 2026 per SPRY's latest filing, from -$245.0 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$201.0 million in Q1 2026 and troughed at -$314.0 million in Q4 2024.
- A 5-year average of -$250.1 million and a median of -$252.2 million in 2023 frame the typical range for Enterprise Value.
- The widest YoY moves for Enterprise Value: up 32.16% in 2022, down 356.82% in 2022.
- Over 5 years, Enterprise Value stood at -$274.4 million in 2022, then increased by 16.77% to -$228.4 million in 2023, then sank by 37.51% to -$314.0 million in 2024, then climbed by 21.98% to -$245.0 million in 2025, then advanced by 17.97% to -$201.0 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$201.0 million, -$245.0 million, and -$288.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | -143.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -143.85 Mn |
| Mar 31, 2026 | -200.97 Mn |
| Dec 31, 2025 | -244.99 Mn |
| Sep 30, 2025 | -288.21 Mn |
| Jun 30, 2025 | -240.13 Mn |
| Mar 31, 2025 | -275.73 Mn |
| Dec 31, 2024 | -314.02 Mn |
| Sep 30, 2024 | -204.62 Mn |
| Jun 30, 2024 | -218.74 Mn |
| Mar 31, 2024 | -223.63 Mn |
| Dec 31, 2023 | -228.36 Mn |
| Sep 30, 2023 | -241.90 Mn |
| Jun 30, 2023 | -252.21 Mn |
| Mar 31, 2023 | -264.55 Mn |
| Dec 31, 2022 | -274.38 Mn |
| Sep 30, 2022 | -266.62 Mn |
| Jun 30, 2022 | -257.98 Mn |
| Mar 31, 2022 | -253.85 Mn |
| Dec 31, 2021 | -60.06 Mn |
| Sep 30, 2021 | -300.66 Mn |